Reaction
Biliary Tract Infection reporting signals
As of the last recalculation, Biliary Tract Infection appears in 603 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is DURVALUMAB (PRR 143.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Durvalumab | 74 | 143.0 | 143.5 |
| Gemcitabine Hydrochloride | 128 | 105.4 | 105.7 |
| Gemcitabine | 81 | 81.8 | 82.0 |
| Paclitaxel | 110 | 46.7 | 46.7 |
| Ursosiol | 22 | 40.5 | 40.6 |
| Ursodiol | 24 | 39.6 | 39.6 |
| Irinotecan Hydrochloride | 10 | 27.3 | 27.3 |
| Entecavir | 8 | 24.0 | 24.0 |
| Pancrelipase | 24 | 22.3 | 22.3 |
| Atezolizumab | 23 | 21.2 | 21.2 |
| Prochlorperazine | 16 | 20.4 | 20.5 |
| Oxaliplatin | 35 | 17.2 | 17.2 |
| Fluorouracil Cream, 0.5% | 35 | 16.8 | 16.8 |
| Fluorouracil | 35 | 16.5 | 16.5 |
| Ado-Trastuzumab Emtansine | 4 | 16.5 | 16.5 |
| Paclitaxel (Aibumin-Bound) | 31 | 13.7 | 13.7 |
| Nivolumab | 32 | 12.0 | 12.0 |
| Erlotinib Hydrochloride | 4 | 11.1 | 11.1 |
| Erlotinib | 3 | 10.7 | 10.7 |
| Polatuzumab Vedotin | 3 | 10.7 | 10.7 |
| Trifluridine And Tipiracil | 3 | 9.7 | 9.7 |